![]() |
|
|
Vol. 301, Issue 3, 878-883, June 2002
Mallinckrodt Institute of Radiology, Washington University School
of Medicine, St. Louis, Missouri (T.J.M., C.P.D., A.Z.S., R.L.,
M.J.W.); Geriatric Research, Education and Clinical Center, Veterans
Affairs Medical Center-St. Louis, and Saint Louis University School of
Medicine, Division of Geriatrics, Department of Internal Medicine, St.
Louis, Missouri (W.A.B.); Amgen, Inc., Thousand Oaks, California
(C.L.F., S.A., D.M., C.P.L); and Eli Lilly and Company, Indianapolis,
Indiana (D.C.L.)
Human obesity may be caused by a resistance to circulating
leptin. Evidence from rodents and humans suggests that a major component of this resistance is an impairment in the ability of the
blood-brain barrier (BBB) to transport leptin from the blood to the
brain. One potential way to bypass the BBB is by administering leptin
into the intrathecal (i.t.) space. To be effective, i.t. leptin would
have to move caudally from the site of injection, enter the cranium,
and reach the hypothalamic arcuate nucleus at the base of the pituitary
fossa. However, many substances, especially small, lipid-soluble
molecules, do not diffuse far from the site of i.t. injection but are
resorbed back into blood. To determine whether i.t. leptin can move
caudally, we injected leptin conjugated to
diethylenetriaminepentaacetic acid (DTPA) and labeled with
68Ga (G-Ob) into the lumbar space of three baboons.
We also studied unconjugated DTPA labeled with 68Ga, which
did not move up the spinal cord but rapidly appeared in blood after
i.t. injection. In contrast, G-Ob steadily moved toward the cranium and
had reached the hypothalamus 91 and 139 min after i.t. injection in two
baboons. We estimated the concentration of leptin in the hypothalamic
region to be at least 8 ng/ml, which is about 40 times higher than
cerebrospinal fluid levels in normal weight humans and about 4 times higher than the highest level ever recorded after the peripheral
administration of leptin. In a third baboon, the leptin neither moved
caudally nor appeared in the blood. We conclude that leptin
administered i.t. can reach the hypothalamus in therapeutic
concentrations, although there is considerable individual variation.
This article has been cited by other articles:
![]() |
W. A. Banks, M. J. During, and M. L. Niehoff Brain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 469 - 475. [Abstract] [Full Text] [PDF] |
||||